SHANGHAI MICROPORT EP MEDTECH CO., LTD. Shanghai MicroPort EP MedTech Co., Ltd. Stock
Equities
688351
CNE100005PG9
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.89 CNY | +1.88% |
|
+0.42% | -6.86% |
| Sales 2024 * | 470M 64.91M | Sales 2025 * | 662M 91.43M | Capitalization | 11.24B 1.55B |
|---|---|---|---|---|---|
| Net income 2024 * | 35M 4.83M | Net income 2025 * | 73M 10.08M | EV / Sales 2024 * | 22.6 x |
| Net cash position 2024 * | 639M 88.27M | Net cash position 2025 * | 726M 100M | EV / Sales 2025 * | 15.9 x |
| P/E ratio 2024 * |
315
x | P/E ratio 2025 * |
155
x | Employees | 577 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 19.29% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.88% | ||
| 1 week | +0.42% | ||
| Current month | -6.39% | ||
| 1 month | -6.39% | ||
| 3 months | -6.68% | ||
| 6 months | -9.85% | ||
| Current year | -6.86% |
1 week
22.70
24.77
1 month
22.7028.49
Current year
18.5928.75
1 year
15.4428.75
3 years
11.7130.36
5 years
11.7130.36
10 years
11.7130.36
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Yong Sun
CEO | Chief Executive Officer | 52 | 10-07-31 |
Yu Zhu
DFI | Director of Finance/CFO | 50 | 15-11-30 |
Yu Qian Gu
BRD | Director/Board Member | 41 | 14-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhe Yi Gu
CHM | Chairman | 40 | 19-02-21 |
Yi Zheng Luan
BRD | Director/Board Member | 39 | 20-11-26 |
Guo Wang Zhang
BRD | Director/Board Member | 51 | 19-02-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 23.89 | +1.88% | 1,181,621 |
| 24-05-30 | 23.45 | -0.51% | 799,184 |
| 24-05-29 | 23.57 | -2.60% | 1,039,111 |
| 24-05-28 | 24.2 | +0.62% | 1,887,020 |
| 24-05-27 | 24.05 | +4.43% | 2,984,859 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
Shanghai Microport EP Medtech Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of medical equipment. The Company is focused on the fields of electrophysiology intervention treatment and ablation treatment, and it is committed to providing integrated diagnosis and ablation treatment solution with precision intervention navigation at its core. The Companyâs main products are heart electrophysiology equipment and related supplies. The Company distributes products both in the domestic market and to overseas markets, including France, Italy, and Spain, among others.
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
23.89
CNY
Average target price
28.11
CNY
Spread / Average Target
+17.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.86% | 1.52B | |
| -27.52% | 16.28B | |
| -40.04% | 2.96B | |
| +15.16% | 1.79B | |
| +38.67% | 1.33B | |
| -15.36% | 968M | |
| +3.53% | 840M | |
| -26.08% | 833M | |
| +23.58% | 630M | |
| -24.63% | 619M |
- Stock Market
- Equities
- 688351 Stock
